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Objectives. The aim of the present study was to examine the 
relation between the plasma levels of the atrial peptide N-terminal 
proatriai natriuretic factor (proANF) measured during the 1st 
12 h after myocardial infarction and 1-year mortality. 
Background. The atrial peptides atrial natriuretic factor and 
N-terminal proANF are released from cardiac atria secondary to 
increased atrial pressures. The plasma levels of both peptides 
have been found to be related to long-term prognosis when 
measured in the subacute phase of myocardial infarction. 
Methods. The study was of a retrospective case-control design 
studying patients enrolled in the Thromholysis in Myocardial 
Infarction (TIMI) II trial. Seventy-six patients who died within 
the 1st year of enrollment in the trial were matched with another 
76 patients who survived. N-terminal proANF was analyzed by 
radioimmunoassay t enrollment (no later than 4 h after the start 
of chest pain) and at 50 min, 5 h and 8 h after enrollment. 
Results. At all studied time points the peptide levels were 
significantly higher in the case group than in the control group. At 
8 h after enrollment, an N-terminal proANF value above a cutoff 
point of 1,500 pmol/liter was associated with an odds ratio for 
death of 3.9. 
Conclusions. The plasma level of N-terminal proANF, when 
measured during the 1st 12 h after the onset of chest pain, is 
related to 1-year mortality after myocardial infarction. Together 
with previous findings, these results suggest that N-terminal 
proANF measurements represent a valuable supplement to cur- 
rently used prognostic indicators after myocardial infarction. 
(J Am Coil Cardiol 1995;26:1452-6) 
The report in 1981 by deBold et al. (1) that atrial extracts 
contained a potent natriuretic substance l d to the discovery of 
atrial natriuretic factor (2). Atrial natriuretic factor is a peptide 
hormone stored in atrial granules as a 126-amino acid prohor- 
mone (3). On secretion, the prohormone issplit into the active 
atrial natriuretic factor moiety and the remaining N-terminal 
part called N-terminal proatrial natriuretic factor (N-terminal 
proANF, subsequently referred to as proANF) (4,5). 
The main regulatory mechanism for atrial peptide secretion 
is increased atrial wall stretch secondary to increased atrial 
pressures (6,7). On the basis of this regulatory mechanism, it 
has been suggested that the plasma concentrations of atrial 
peptides may serve as markers for increased atrial pressures in 
cardiovascular disease. Supporting this view, data from previ- 
ous studies confirm that the plasma levels of atrial peptides 
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correlate with invasively measured atrial pressures (8,9) and 
are increased in patients with chronic heart failure and after 
acute myocardial infarction (10-13). 
The most important determinant of long-term prognosis 
after myocardial infarction is the residual left ventricular 
function as reflected in left ventricular ejection fraction and 
ventricular volumes (14,15). Reduced left ventricular function 
also leads to increases in left atrial pressure (16). Conse- 
quently, a relation has been found between plasma levels of 
atrial natriuretic factor and proANF and long-term prognosis 
in infarct survivors (17,18). Recently, we (19) found that the 
plasma level of proANF was a powerful independent predictor 
of long-term prognosis when measured 3 to 16 days after 
infarction. Furthermore, proANF was found to be a signifi- 
cantly stronger prognostic indicator than atrial natriuretic 
factor itself. 
On the basis of ease of measurement and in vitro stability, 
proANF plasma levels may constitute a new and valuable tool 
in the selection of high risk patients after myocardial infarc- 
tion. Previous studies examining the relation between atrial 
peptides and prognosis have focused on measurements in the 
subacute phase of infarction (3 to 16 days after the onset of 
chest pain). In the present study we examined whether a 
relation to prognosis exists even when measurements are 
performed in the acute phase of infarction. In a case-control 
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study we measured the plasma levels of proANF at four 
different time points during the 1st 12 h after the onset of chest 
pain and related these levels to mortality after 1 year. 
Methods 
The present study was designed as a retrospective case- 
control study of patients enrolled in the Thrombolysis in 
Myocardial Infarction (TIMI) II trial (20). The TIMI II trial 
studied patients treated with infusion of recombinant tissue- 
type plasminogen activator (rt-PA) within 4 h of the onset of 
chest pain associated with electrocardiographic ST segment 
elevation. The trial was a randomized trial comparing an 
invasive versus a conservative treatment s rategy with regard to 
coronary catheterization and revascularization. The effect of 
immediate versus deferred treatment with beta-adrenergic 
blocking agents was also investigated. The details of the TIMI 
II protocol and the results of the main study are reported 
elsewhere (20). 
Of a total of 2,819 patients who received a dose of 100 mg 
of rt-PA, there were 76 patients who died within the 1st year of 
enrollment and from whom blood samples from the 8-h time 
point were available. These patients erved as the case group 
for this study. Another 76 patients who survived the 1st year 
served as the control group; these patients were selected after 
being matched to the case patients with regard to clinical unit, 
gender, site of myocardial infarction (anterior vs. other), age 
(_+5 years) and treatment strategy (invasive vs. conservative). 
The analysis of proANF was made in plasma liquots taken 
from samples collected for blood coagulation studies at four 
time points during the 1st 8 h of the study: 1) immediately 
before the start of rt-PA infusion (at enrollment, no later than 
4 h after the start of chest pain), and 2) 50 rain, 3) 5 h, and 
4) 8 h thereafter. The samples were collected from a peripheral 
vein (opposite to the limb of rt-PA infusion) into vacutainers 
containing ethylenediaminetetraacetic acid (4.5 retool/liter), 
PPACK (20 /stool/liter) and aprotinin (150 KIU/ml). After 
separation of plasma the tubes were sent in batches in a frozen 
condition to the TIMI II coagulation core laboratory (Univer- 
sity of Vermont, Burlington, Vermont) and stored for 5 to 7 
years at -135°C before analysis of proANF. The samples had 
undergone one freeze-thaw cycle before analysis. 
Radioimmunoassay. The analysis of proANF was per- 
formed by measuring immunoreactive atrial natriuretic factor 
(1-98) by radioimmunoassay directly in plasma without prior 
extraction of peptide. The method employed was that of 
Sundsfjord et al. (4) using the same polyclonal antibody. This 
antibody recognizes immunoreactive epitopes between amino 
acids 7 and 30 of the atrial natriuretic factor (1-98) peptide. As 
documented by Sundsfjord et al. (4), the main molecular form 
measured is intact atrial natriuretic factor (1-98), although 
there is some heterogeneity on gel filtration indicating mea- 
surement of peptides hortened at the N- or C-terminal. 
The detection limit for the assay was: 185 pmol/liter. The 
coefficient of variation when analyzing the same sample in 
separate assay runs (between-assay coefficient of variation) 
was: 7.1% (sample mean 389 pmol/liter, n = 10), 5.1% (sample 
mean 889 pmol/liter, n = 10) and 5.2% (sample mean 1,858 
pmol/liter, n --- 10). The coefficient of variation when analyzing 
several aliquots of the same sample within one assay run 
(within-assay coefficient of variation) was: 5.3% (sample mean 
359 pmol/liter, n = 10), 2.4% (sample mean 754 pmol/liter, n = 
10) and 8.5% (sample mean 8,137 prnol/liter, n = 10). One 
hundred thirty-four healthy persons (60 +- 16 years of age) 
from Oslo, Norway were used as normal control subjects for 
proANF. 
The immunoreactivity of atrial natriuretic factor (1-98) is 
not influenced by two freeze-thaw cycles (lst thaw 851 + 
819 pmol/liter, 2rid thaw 868 + 569 pmol/liter, n = 17, p = 0.8). 
It has also been found stable during storage for up to 4 days at 
room temperature (21) and for up to 2.5 years during storage 
at -20°C (baseline 851.2 +- 818.8 pmol/liter, 2.5 years 867.9 + 
568.8 pmol/liter, n = 17, p = 0.8). 
Statistics. Statistical analyses of categoric data were per- 
formed by using chi-square tests; analyses of continuous data 
were performed by using t tests. ProANF levels were compared 
by using paired t tests and repeated measures analyses of 
variance (ANOVA). To assess whether other baseline vari- 
ables in addition to the matching variables affected the relation 
between proANF and 1-year mortality, a conditional logistic 
regression (22) was performed controlling for the effect of 
prior myocardial infarction, hypertension, diabetes, body 
weight, serum ereatinine, presence of pulmonary tales and 
presence of atrial fibrillation. The odds ratio and 95% confi- 
dence limits were calculated from the 2 × 2 table using the 
case-control study design (23). 
Results 
The baseline characteristics of the case and control patients 
are summarized in Table 1. In addition to being matched for 
five characteristics including age, gender and infarct location, 
the control and case patients had a similar cardiovascular risk 
profile with regard to history of diabetes, hypertension and 
prior congestive heart failure. However, the case group showed 
a significantly higher frequency of a prior myocardial infarction 
(33% vs. 13%, p < 0.01) and a higher mean serum creatinine 
level (1.2 vs. 1.1 mg/dl, p = 0.02). 
Univariate analysis. The results of proANF measurements 
in the two groups of patients are summarized in Figure 1 and 
Table 2. At enrollment, he mean plasma proANF was 1,811 _ 
1,128 pmol/liter in the case group and 1,353 ___ 597 pmol/liter in 
the control group (p = 0.004). During the next 8 h there was a 
parallel reduction in proANF levels (33%) in both groups. At 
all time points, however, the mean value in the case group was 
significantly higher than that in the control group. This finding 
was confirmed by univariate analysis (Table 2) and by repeated 
measures ANOVA for the case-control pairs having complete 
data at all four time points (n = 42, case vs. control: p = 0.003, 
time: p : 0.001). 
Compared to the age-adjusted reference level for healthy 
control subjects (97.5 percentile) proANF plasma levels at 
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Table 1. Comparison of Baseline Characteristics of Case and Control Patients 
Case Group Control Group 
(n = 76) (n = 76) 
P 
No. % No. % Value 
% Male 54 71% 54 71% Matching variable 
Anterior MI 56 74% 56 74% Matching variable 
Invasive treatment strategy 27 36% 31 41% Matching variable 
History of diabetes 18 24% 13 17% 0.31 
History of hypertension 38 50% 34 45% 0.52 
Prior MI 25 33% 10 13% < 0.01 
Prior CHF 2 3% 1 1% 0.56 
Rales on initial physical examination 16 21% 13 17% 0.54 
Presence ofatrial fibrillation or flutter 4 5% 3 4% 0.70 
Age (yr) 63.4 + 8.2 62.9 _+ 8.0 Matching variable 
Body weight (kg) 80.8 -+ 15.2 78.9 +_ 15.9 0.47 
Serum creatinine (mg/dl) 1.2 _+ 0.35 1.1 _+ 0.26 0.02 
Data presented are number (%) of patients or mean value + SD. CHF = congestive h art failure; MI = myocardial 
infarction. 
enrollment were above normal in 68% of the case patients and 
60% of the control patients. At 8 h 36% of the case patients 
and 21% of the control patients showed values above the 
reference level. 
To estimate the relative risk of death in relation to proANF 
level, a cutoff point of 1,500 pmol/liter that gave the highest 
odds ratios was selected (Table 3). A proANF value >1,500 
pmol/liter at enrollment and at 4 and 8 h was associated with 
a significantly increased risk of death; this increased risk was 
greatest (odds ratio = 3.9) at 8 h after enrollment. 
Multivariate analysis. To assess whether baseline variables 
other than the matching variables affected the relation between 
proANF and long-term mortality, a multivariate logistic re- 
gression was performed controlling for the effect of prior 
myocardial infarction, hypertension, diabetes, body weight, 
serum creatinine level and presence of pulmonary rales or 
atrial fibrillation on the initial physical examination (Table 2). 
After controlling for these variables, the increased risk of 
death associated with higher proANF plasma concentration 
Figure 1. Plasma levels of N-terminal proatrial natriuretic factor 
(ProANF) plotted against ime of measurement i  case and control 
groups. Data shown are mean value ± SD. *p < 0.05. 
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remained statistically significant at enrollment and at 5 and 8 h 
after enrollment. 
Discuss ion  
In the present study the plasma concentration of proANF 
measured in the acute phase of myocardial infarction was 
higher in patients who died within the subsequent year of 
observation than in matched survivors. This finding of a 
relation between proANF and mortality is consistent with our 
earlier study (19) showing that proANF level is a strong and 
independent prognostic indicator when measured 3 to 15 days 
after infarction in patients with left ventricular dysfunction. 
The present study extends this observation to a group of 
patients with myocardial infarction not selected for left ven- 
tricular dysfunction who were aggressively treated with throm- 
bolytic agents. Furthermore, even with very early measure- 
ment, within 4 h of the onset of chest pain, proANF levels were 
related to survival, and this relation was consistent 8 h later. 
Suggested mechanism of prognostic relation. The main 
stimulus for release of atrial natriuretic factor prohormone 
into the bloodstream is increased atrial wall stretch secondary 
to an increase in atrial pressure. Myocardial necrosis in a 
segment of the left ventricle leads to a reduction in systolic as 
well as diastolic function (16,24). Both of these factors may 
lead to increased left atrial pressures. The observed ifferences 
in proANF levels between the groups suggest hat the case 
patients had higher atrial pressures than did the control 
patients. Thus, our results are consistent with earlier findings 
(25) that increased pulmonary capillary wedge pressure mea- 
sured within the 1st 12 h after infarction is related to poor 
long-term prognosis. Because myocardial infarction may acti- 
vate ventricular secretion of atrial natriuretic factor (26), some 
of the proANF increase observed may stem from this source as 
well. 
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Table 2. N-Terminal Proatrial Natriuretic Factor Plasma Levels (pmol/liter) at the Four Studied 
Time Points 
Case Group Control Group p Adjusted 
Time Pairs (no.) (mean _+ SD) (mean _+ SD) Value p Value* 
Enrollment 57 1,811 _+ 1,128 1,353 -+ 597 0.004 0.04 
50 min 63 1,603 +- 921 1,291 -- 662 0.02 0.09 
5 h 72 1,374 _+ 781 1,056 _+ 409 0.001 0.02 
8 h 76 1,215 _+ 664 912 _+ 364 < 0.001 0.007 
*Conditional logistic regression adjusting for prior myocardial nfarction, hypertension, diabetes, body weight, plasma 
creatinine and presence ofpulmonary ales and atrial fibrillation on initial physical examination. 
proANF time pattern. A large proportion of the patients 
showed elevated peptide values at enrollment hat decreased 
with time during the 1st 12 h. This observation is consistent 
with results of echocardiographic studies in which left ventric- 
ular function, depressed in the early phase of infarction, seems 
to improve during the 1st 24 h after thrombolytic therapy (27). 
The pattern of decreasing proANF levels is similar to earlier 
findings of decreasing atrial natriuretic factor levels on the day 
of hospital admission for myocardial infarction (28). These 
parallel findings may be explained by the equimolar secretion 
of the two parts of the atrial natriuretic factor prohormone. 
However, the plasma levels of proANF were up to 200-fold 
higher than those reported for atrial natriuretic factor, a 
discrepancy attributed to the difference in half-life of the 
peptides (29). 
Study limitations. Several possible limitations of this study 
should be noted. First, this was a moderate sized case-control 
study and the relative risk of a high proANF level can 
therefore only be estimated. Clearly, a prospective study will be 
needed to define more accurately the relative and absolute risk 
of elevated proANF levels after myocardial infarction. Second, 
proANF was previously shown to be a prognostic indicator 
independent of left ventricular ejection fraction (19). Data 
from ejection fraction measurements were not available in this 
study. However, consistent with our earlier findings, the rela- 
tion between proANF and prognosis was present even when 
Table 3. Mortality (groups combined) and Odds Ratios for Death 
Within 1 Year for Patients With N-Terminal Proatrial Natriuretic 
Factor Plasma Levels >1,500 or <-1,500 pmolfliter 
95% 
Percent Odds Confidence 
Dead Ratio Interval 
Enrollment 
---1,500 37.7 
>1,500 64.2 3.0 1.4-6.3 
lh 
-<1,500 44.2 
>1,500 59.2 1.8 0.9-3.8 
4h 
-<1,500 42.7 
>1,500 73.5 3.7 1.6-8.5 
8h 
-<1,500 44.9 
>1,500 76.0 3.9 1.5-9.9 
adjusting for clinical variables uch as infarct location and prior 
myocardial infarction that influence ejection fraction. 
Third, the elevated proANF concentrations seen in the 
present study patients may be explained not only by increased 
cardiac secretion, but also by decreased plasma clearance. The 
clearance of proANF from plasma has not been thoroughly 
studied. Experimental data (30) indicate that renal excretion is 
the main clearance mechanism. In multivariate analysis of 
patients with myocardial infarction, we found (unpublished 
data) that an increase in plasma creatinine of 0.1 mg/dl 
corresponded to an increase of 40 pmol/liter in proANF. 
Consequently, most of the increase in proANF values is best 
explained by changes in the cardiac secretion of the peptide. 
Clinical relevance. The present results supplement earlier 
reported findings (18,19) of a relation between atrial peptide 
levels after myocardial infarction and long-term prognosis. 
However, no previous tudy has studied this relation during the 
1st 12 h after the onset of chest pain. Taken together with 
earlier findings, our results confirm the potential role of 
proANF as a clinically useful prognostic marker in these 
patients and underscore that it may be of use also when 
measured on the day of hospital admission. Measurement of 
proANF supplements currently applied prognostic indicators 
after myocardial infarction in an independent way and there- 
fore contributes to the prognostic evaluation of these patients. 
Furthermore, in contrast to atrial natriuretic factor, the in vitro 
stability of proANF combined with its relative ease of mea- 
surement makes it of practical use in the daily clinical setting. 
Collectively, these characteristics position proANF measure- 
ments as a promising new tool in the stratification of patients 
with myocardial infarction. 
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